Fairvalue-Calculator Fairvalue-Calculator
EN DE

HLB Co (028300) Fair Value & Analysis

Healthcare · KR · Market cap 6.6T KRW

Price50,300 KRW
Fair Value12,758 KRW
Upside-74.6%
Quality83/100
Evidence: Low Range 9,569 KRW – 15,948 KRW

Analysis

HLB Co (028300) currently trades at 50,300 KRW, while our model-based Fair Value estimate is 12,758 KRW — implying the stock looks roughly 74.6% overvalued today. We read business quality at 83/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

HLB Co., Ltd. manufactures and constructs lifeboats and glass fiber pipes in South Korea and internationally. It engages in the repair and inspection of lifeboats; fabrication and installation of pipes; development and manufacturing of biopharmaceuticals products, such as anti-cancer drugs; and manufacture and sale of medical devices, as well as manufacture and sale of quasi-drugs products, including alcohol swabs, sampling tools, etc. The company is also involved in e-commerce, investment, and financing activities. Additionally, it develops biological drugs with MoA to infectious diseases. HLB Co., Ltd. was founded in 1975 and is headquartered in Ulsan, South Korea.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.